Compare Novartis AG (NVS) vs United Microelectronics Corp (UMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs United Microelectronics Corp — how do they compare? Novartis AG trades at $153.88 (market cap $290.25B), while United Microelectronics Corp trades at $21.15 (market cap $51.00B). The key difference: Novartis AG is far larger — about 5.7× United Microelectronics Corp's market cap, and Novartis AG pays the higher dividend (3.17%). Which is the better fit depends on your goals.
| NVS | UMC | |
|---|---|---|
Market Cap | $290.25B | $51.00B |
Sector | Health | Technology |
52-Week High | $168.62 | $28.02 |
52-Week Low | $113.50 | $6.58 |
Enterprise Value | $330.27B | $48.57B |
Dividend Yield | 3.17% | 2.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $153.87, showing minimal daily movement with a slight 0.07% gain. The stock exhibits bearish technical signals from moving averages despite a neutral oscillator reading. Fundamentally, the company reported strong Q2 2026 earnings that beat expectations, with revenue of $56.67 billion in 2025 and robust profitability margins, including a net income margin of 23.92%. Recent news highlights successful drug launches offsetting generic competition pressures.
The outlook remains cautiously optimistic as new medicines drive growth, but risks include patent expirations and pipeline trial results. Analyst sentiment is mixed with 68% hold ratings, reflecting balanced views on execution versus competitive threats. Investment appeal hinges on sustained drug innovation and margin stability amid industry headwinds.
UMC trades at $21.19, down 0.28% on the day, with a bullish technical signal from oscillators but bearish moving averages. The company reported Q1 2026 EPS of $0.20, beating expectations, and maintains a net income margin of 20.25%. Recent news highlights mass production of silicon photonics ICs and strong June 2026 sales growth of 22.85% year-over-year.
Outlook is supported by earnings beats and specialty technology demand, but risks include valuation above sector peers and competitive pressures. Analysts are mixed with 26.67% buy ratings, suggesting cautious optimism amid solid execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About United Microelectronics Corp
Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 7% market share in 2021, according to Gartner, after TSMC and GlobalFoundries. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the U.S. and South Korea. UMC features a diverse customer base including Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.
Read more on UMC →
